Skip to main content
. Author manuscript; available in PMC: 2016 Jun 8.
Published in final edited form as: Hypertens Res. 2014 Sep 11;38(1):21–29. doi: 10.1038/hr.2014.132

Figure 5. Dose-dependent inhibition of on the anti-inflammatory effect of AT2R agonist (C21) on TNF- α production by neutralizing interleukin-10 (IL-10) antibody.

Figure 5

Cells were incubated with increasing doses of neutralizing IL-10 antibody (0.125–2.5µg/ml) for 30 minutes prior to C21 pre-treatement (1µmol/l). Cells were activated with LPS (1µg/ml) 60 minutes after addition of C21. Cytokine concentrations in media were measured by ELISA. Data are represented as mean ± SEM. * indicates p<0.05 vs LPS, # indicates p<0.05 vs LPS+C21 treated THP-1 macrophages (n=5).